A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)
Diseases of the Endocrine System | Genetics - Adult
What is the purpose of this trial?
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.
- Ages18 years - 60 years
- Trial withVivet Therapeutics, SAS
- Start Date08/01/2021
- End Date07/31/2023
- Last Updated09/23/2021
- Study HIC#2000028887